Arrowhead Pharmaceuticals (NASDAQ:ARWR) is a biopharmaceutical company specializing in the discovery, development and commercialization of ribonucleic acid interference (RNAi) therapeutics. Utilizing its proprietary Targeted RNAi Molecule (TRiMTM) platform and advanced delivery systems, Arrowhead aims to silence disease-causing genes and address a broad range of unmet medical needs. The company’s pipeline spans multiple therapeutic areas including cardiovascular, metabolic, respiratory, renal, hepatic and infectious diseases.
Founded in 2008 and headquartered in Pasadena, California, Arrowhead has built a robust research and development organization with both in-house and collaborative efforts. Since its initial public offering in 2014 (NASDAQ: ARWR), the company has advanced several programs into clinical trials, including candidates targeting chronic hepatitis B, alpha-1 antitrypsin deficiency and hemophilia. Arrowhead’s scientific team has published extensively on mechanisms of RNAi and delivery strategies, contributing to a deeper understanding of gene silencing therapeutics.
Arrowhead maintains strategic partnerships and research collaborations with major pharmaceutical firms to enhance its development capabilities and accelerate clinical progress. These collaborations provide access to complementary expertise, specialized resources and expanded geographic reach. The company’s research sites are located across the United States, and its clinical trials also engage investigators and patients in Canada, Europe and Asia.
Under the leadership of Chief Executive Officer Christopher Anzalone and Chief Financial Officer Quentin Magee, Arrowhead continues to expand its pipeline and strengthen its technology platforms. The company is committed to rigorous clinical development, regulatory engagement and eventual commercialization of RNAi-based medicines that offer new treatment options for patients with serious diseases worldwide.
